Oncology Archives - WuXi Biology

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...

Radionuclide Drug Conjugates in Anticancer Treatment

Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...

Integrated Platform Supporting ASO Drug Discovery

Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...

DLL3‑related Tumor Models in Humanized Mice

OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well...

Spontaneous Mouse Tumor-derived Syngeneic Models

Spontaneous mouse tumor-derived syngeneic models are valuable tools in preclinical cancer research. These tumor models offer unique advantages because immunotherapies...

PBMC Humanized Tumor Models for Evaluating T-cell Engagers

T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...

Integrated Screening and Assay Capabilities Facilitate Peptide Drug Discovery

Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity,...

Knowledge Library